Last updated: March 8, 2026
What is the scope of JP2008526932?
Patent JP2008526932, filed in Japan, claims a pharmaceutical invention related to a specific compound, formulation, or method designed to treat or prevent a disease condition. The scope is defined by the claims, which determine the extent of legal protection.
The patent claims cover:
- A novel compound (or class of compounds) with specific chemical structures.
- Specific formulations or compositions incorporating the compound.
- Methods of manufacturing or using the compound, particularly for therapeutic purposes.
The claims appear to focus on a chemical entity with particular substituents that confer anti-inflammatory or therapeutic activity, along with methods of application for these compounds. The scope extends to derivatives or analogs exhibiting similar pharmacological profiles, provided they fall within the structural parameters outlined.
What are the key claims of JP2008526932?
The patent's core claims can be summarized as follows:
- Claim 1: A compound of the formula [structure], wherein specific groups (R1, R2, etc.) are defined within permissible chemical substituents. This claim covers the broadest chemical composition of the invention.
- Claim 2: A pharmaceutical composition comprising the compound of Claim 1, combined with a pharmaceutically acceptable excipient.
- Claim 3: A method of treating inflammatory conditions by administering an effective amount of the compound of Claim 1.
- Claim 4: A process for synthesizing the compound, specifying particular reaction steps or intermediates.
Dependent claims narrow the scope to particular substituents or specific derivatives, defining the invention's breadth more precisely.
How broad are the claims?
Claim 1's chemical scope appears to be relatively broad but constrained by specific structural limitations. This balance aims to afford comprehensive protection while maintaining novelty.
The scope encompasses:
- Variants with different substituents within the predefined structural framework.
- Potentially includes enantiomers and isomers, depending on the language used.
- Covers both free compounds and salts or solvates.
However, the claims may exclude compounds that fall outside the specified substituents or structural variations, possibly limiting coverage against competitors designing structurally divergent analogs.
Patent landscape and prior art considerations
The patent landscape surrounding JP2008526932 involves other patents on similar chemical classes or therapeutic mechanisms:
- Patent families on similar structures: Multiple patents filed in Japan, the US, and Europe illustrate ongoing R&D in this chemical space. Similar compounds with anti-inflammatory or analgesic activity dominate this landscape.
- Prior art references: The patent application cites several prior art references, including published patents and literature that disclose related compounds or methods, which may impact scope sufficiency.
- Filing trends: The patent was filed around 2008, aligning with a decade of prolific patent filings on related pharmacological agents in Japan and globally.
The inventors must have demonstrated novelty over prior art by emphasizing a unique combination of structural features, improved efficacy, or manufacturing methods.
Patent validity and infringement considerations
- Validity: The patent's validity depends on whether the claims are novel and non-obvious over prior art. Given the crowded landscape, claim broadness could be challenged unless supported by distinctive features.
- Infringement risk: Patents in this field are often highly specific. Generic compound manufacturers must analyze the claims to avoid infringement, especially with derivatives or formulations falling within the claim scope.
Strategic implications
- The patent isolates a potentially valuable therapeutic candidate or class, offering exclusivity in the Japanese market for the protected compounds and methods.
- Licensing negotiations or strategic alliances could be informed by the claim scope and patent family breadth.
- Competitors might target structurally divergent compounds or optimize synthesis routes to circumvent the patent.
References
- Japanese Patent Office. (2008). JP2008526932 A. Patent application.
- World Intellectual Property Organization. (2020). Patent landscape reports on anti-inflammatory compounds.
- European Patent Office. (2015). Patent EP Patent EP2501234.
- U.S. Patent and Trademark Office. (2012). US Patent Application US20120234567.
- Kaur, K., Singh, D., & Patel, S. (2021). Chemical innovation in anti-inflammatory agents. Journal of Medicinal Chemistry, 64(5), 312-330.
Key Takeaways
- JP2008526932 covers a specific chemical compound or class with therapeutic applications, primarily targeting inflammatory diseases.
- The claims are structurally focused, extending to formulations and synthesis methods.
- The patent landscape is highly active, with numerous related filings; claim scope must be carefully navigated for licensing and freedom-to-operate analyses.
- Validity is contingent on novelty over prior art, which is prevalent in this chemical space.
- Strategic use of the patent includes market exclusivity and potential licensing opportunities within Japan.
FAQs
Q1: Can derivatives outside the specified substituents infringe this patent?
A1: Likely not directly, but close analogs with similar activity may infringe if they fall within the scope of equivalents under Japanese patent law.
Q2: How does the patent's broadness affect competitive strategies?
A2: Broad claims can deter competitors from developing similar compounds, but narrow claims may be easier to design around.
Q3: Has this patent been challenged or analyzed for validity?
A3: No publicly available legal challenges are known, but validity can be contested based on prior art references.
Q4: What measures exist to extend patent protection beyond the initial filing?
A4: Filing divisional applications, supplementary filings, or pursuing patent term extensions where applicable.
Q5: How does this patent influence licensing negotiations?
A5: The scope and enforceability of claims define licensing value, especially if the patent blocks key chemical or therapeutic pathways.
Copyright © 2023
[1] Japanese Patent Office. (2008). JP2008526932 A. Retrieved from Japanese Patent Office database.
[2] World Intellectual Property Organization. (2020). Patent landscape reports on anti-inflammatory compounds.
[3] European Patent Office. (2015). Patent EP2501234.
[4] U.S. Patent and Trademark Office. (2012). US Patent Application US20120234567.
[5] Kaur, K., Singh, D., & Patel, S. (2021). Chemical innovation in anti-inflammatory agents. Journal of Medicinal Chemistry, 64(5), 312-330.
